Christopher Richard Anzalone Arrowhead Pharmaceuticals, Inc. (ARWR) insider trading activity

ARWR Quotes by TradingView

Christopher Richard Anzalone is Chief Executive Officer of ARROWHEAD PHARMACEUTICALS, INC.. Currently has a direct ownership of 3.92 Million shares of ARWR, which is worth approximately $65.8 Million. The most recent transaction as insider was on Dec 20, 2022, when has been sold 234,025 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.92M
3.47% 3M change
5.55% 12M change
Total Value Held $65.8 Million

Christopher Richard Anzalone Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 20 2022
BUY
Grant, award, or other acquisition
-
234,025 Added 5.92%
3,720,714 Common Stock
Dec 16 2022
BUY
Grant, award, or other acquisition
-
18,375 Added 0.52%
3,486,689 Common Stock
Sep 27 2022
SELL
Exercise of conversion of derivative security
$1,258,938 $30.99 p/Share
40,624 Reduced 1.16%
3,468,314 Common Stock
Jul 08 2022
SELL
Sale (or disposition) back to the issuer
-
551,197 Reduced 13.58%
3,508,938 Common Stock
Jul 07 2022
BUY
Exercise of conversion of derivative security
$36,365 $14.54 p/Share
2,501 Added 0.06%
4,060,135 Common Stock
Feb 11 2022
SELL
Open market or private sale
$7,568,260 $51.7 p/Share
146,388 Reduced 3.48%
4,057,634 Common Stock
Feb 11 2022
BUY
Exercise of conversion of derivative security
$759,754 $5.19 p/Share
146,388 Added 3.36%
4,204,022 Common Stock
Jan 07 2022
BUY
Exercise of conversion of derivative security
$61,273 $5.19 p/Share
11,806 Added 0.29%
4,057,634 Common Stock
Jan 01 2022
BUY
Grant, award, or other acquisition
-
800,000 Added 16.51%
4,045,828 Common Stock
Dec 23 2021
BUY
Exercise of conversion of derivative security
$61,273 $5.19 p/Share
11,806 Added 0.36%
3,245,828 Common Stock
Dec 15 2021
SELL
Open market or private sale
$4,096,800 $68.28 p/Share
60,000 Reduced 1.83%
3,219,022 Common Stock
Oct 22 2021
SELL
Open market or private sale
$3,291,500 $65.83 p/Share
50,000 Reduced 1.5%
3,279,022 Common Stock
Oct 20 2021
SELL
Open market or private sale
$993,450 $66.23 p/Share
15,000 Reduced 0.45%
3,329,022 Common Stock
Jan 01 2021
BUY
Grant, award, or other acquisition
-
800,000 Added 19.3%
3,344,022 Common Stock
Dec 30 2020
SELL
Bona fide gift
-
599 Reduced 0.02%
2,544,022 Common Stock
Dec 28 2020
SELL
Bona fide gift
-
1,126 Reduced 0.04%
2,544,621 Common Stock
Dec 18 2020
BUY
Exercise of conversion of derivative security
$220,779 $5.45 p/Share
40,510 Added 1.57%
2,545,747 Common Stock
Dec 09 2020
SELL
Open market or private sale
$2,703,066 $69.89 p/Share
38,676 Reduced 1.52%
2,505,237 Common Stock
Dec 09 2020
BUY
Exercise of conversion of derivative security
$77,739 $2.01 p/Share
38,676 Added 1.5%
2,543,913 Common Stock
Dec 08 2020
SELL
Open market or private sale
$1,109,542 $67.97 p/Share
16,324 Reduced 0.65%
2,505,237 Common Stock
Dec 08 2020
BUY
Exercise of conversion of derivative security
$32,811 $2.01 p/Share
16,324 Added 0.64%
2,521,561 Common Stock
Oct 23 2020
SELL
Open market or private sale
$5,837,000 $58.37 p/Share
100,000 Reduced 3.84%
2,505,237 Common Stock
CRA

Christopher Richard Anzalone

Chief Executive Officer
Pasadena, CA

Track Institutional and Insider Activities on ARWR

Follow ARROWHEAD PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARWR shares.

Notify only if

Insider Trading

Get notified when an Arrowhead Pharmaceuticals, Inc. insider buys or sells ARWR shares.

Notify only if

News

Receive news related to ARROWHEAD PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ARWR